Navigation Links
Singapore nanotechnology combats fatal brain infections
Date:6/28/2009

Doctors may get a new arsenal for meningitis treatment and the war on drug-resistant bacteria and fungal infections with novel peptide nanoparticles developed by scientists at the Institute of Bioengineering and Nanotechnology (IBN) of Singapore and reported in Nature Nanotechnology.

The stable bioengineered nanoparticles devised at IBN effectively seek out and destroy bacteria and fungal cells that could cause fatal infections and are highly therapeutic.

Major brain infections such as meningitis and encephalitis are a leading cause of death, hearing loss, learning disability and brain damage in patients.

IBN's peptide nanoparticles, on the other hand, contain a membrane-penetrating component that enables them to pass through the blood brain barrier to the infected areas of the brain that require treatment. The ability of IBN's peptide nanoparticles to traverse the blood brain barrier offers a superior alternative to existing treatments for brain infections. The brain membrane is impenetrable to most conventional antibiotics because the molecular structure of most drugs is too big to enter the membrane.

"Our treatment damages the structure of the pathogen and literally breaks it apart," said Yiyan Yang, Ph.D., group leader at IBN, one of the research institutes sponsored by Singapore's A*STAR (Agency for Science, Technology and Research).

"Our oligopeptide has a unique chemical structure that forms nanoparticles with membranepenetrating components on their surface," Dr. Yang added. "These nanoparticles can easily enter bacteria, yeast or fungal cells and destabilize them to cause cell death. For example, the nanoparticles cause damage to bacteria cell walls and prevent further bacterial growth."

The IBN research team has demonstrated that these engineered peptide nanoparticles have high antimicrobial activity and are highly effective in killing microbes.

Additionally, the peptide nanoparticles are more powerful in inhibiting the growth of fungal infections than conventionally available anti-fungal drugs such as fluconazole and amphotericin B.

"We are able to kill bacteria better than conventional antibiotics. By attacking the cellular structure of the microbes, our nanoparticles can be used to successfully combat persistant bacterial infections," added IBN scientist Lihong Liu, Ph.D.

Pre-clinical tests have shown that IBN's peptide nanoparticles are biocompatible and cause no damage to the liver or kidneys at tested doses. Highly anti-infective, the therapeutic doses of the peptide nanoparticles are expected to be safe for use because they also do not damage red blood cells.

IBN Executive Director Jackie Y. Ying, Ph.D., said, "Our interdisciplinary research groups have made tremendous progress in finding novel drug and gene delivery avenues for medical treatments. With this peptide nanoparticle, we have found a way through the blood brain barrier and produced a treatment for previously challenging diseases."


'/>"/>

Contact: Cathy Yarbrough
sciencematter@yahoo.com
858-243-1814
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

Related biology news :

1. Singapore scientists elected into National Academy of Sciences
2. Alzheimers, asthma, cancer, malaria and TB focus of new Singapore grants
3. Singapore scientists synthesize gold to shed light on cells inner workings
4. Singapore researchers first to transform carbon dioxide into methanol
5. First tri-continuous mesoporous Silica complex structure developed in Singapore
6. Regulatory molecule for tumor formation or suppression identified by Singapore, US researchers
7. The Earth Observatory of Singapore devoted to the study of earth sciences officially opens
8. Singapore research organisations team up to advance drug discovery using brain tumor stem cells
9. Singapore-US scientists first to develop revolutionary microchip that uses 30 times less energy
10. NTU undergrad is first Singapore champion of an internationally acclaimed engineering competition
11. Singapore research team first place in Brain-Computer Interface contest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)...  higi SH llc (higi) announced today the ... brands, industry thought-leaders and celebrity influencers looking to ... taking steps to live healthier, more active lives. ... has built the largest self-screening health station network ... who have conducted over 185 million biometric screenings.  ...
(Date:11/29/2016)... 29, 2016 Nearly one billion matches per second ... ... DERMALOG is Germany's ... efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification ...
(Date:11/22/2016)... PUNE, India , November 22, 2016 According ... (Single-Factor: (Fingerprint, IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware ... to 2022", published by MarketsandMarkets, the market is expected to grow from ... at a CAGR of 16.79% between 2016 and 2022. ... ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... ... ... There’s a winning streak at Voxx Analytics: the tech company has been ... award last year as well. Employees nominate their companies for the honor, and this ... the tech company’s upbeat environment as a reason. “We don’t answer to Wall Street. ...
(Date:12/9/2016)... ... , ... Aditya Humad, Acting CFO of AxioMed and Managing Partner of KICVentures, ... Axiomed is now gaining interest from Silicon Valley. “It was satisfying to complete the ... to say that, “We expect interest to continue to rise as AxioMed completes its ...
(Date:12/9/2016)... 9, 2016  A platform of orthopedic device technologies ... one step closer to becoming viable options for ... Inc., a start-up company from Philadelphia, ... for these novel absorbable bone fixation and regenerative ... commercial use. The company has leased space within ...
(Date:12/9/2016)... , Dec. 9, 2016 /PRNewswire/ - Portage Biotech Inc. ... PBT.U), is pleased to announce that Biohaven has issued ... New Haven, Connecticut (PRWEB) Dec 9, 2016 ... "Biohaven") announced today that the U.S. Food and Drug ... request covering its drug candidate BHV-0223, an orally dissolving ...
Breaking Biology Technology: